Global Human Papillomavirus Vaccine Market Growth 2025-2031

October 2025 | 89 pages | ID: GFF3A7E53B03EN
LP Information

Abstracts

The global Human Papillomavirus Vaccine market size is predicted to grow from US$ 2352 million in 2025 to US$ 2793 million in 2031; it is expected to grow at a CAGR of 2.9% from 2025 to 2031.

The impact of the latest U.S. tariff measures and the corresponding policy responses from countries worldwide on market competitiveness, regional economic performance, and supply chain configurations will be comprehensively evaluated in this report.

Human papilloma virus (HPV) vaccine is a vaccine that prevents infection by certain types of human papillomavirus.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

LP Information, Inc. (LPI) ' newest research report, the ?Human Papillomavirus Vaccine Industry Forecast? looks at past sales and reviews total world Human Papillomavirus Vaccine sales in 2024, providing a comprehensive analysis by region and market sector of projected Human Papillomavirus Vaccine sales for 2025 through 2031. With Human Papillomavirus Vaccine sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Human Papillomavirus Vaccine industry.

This Insight Report provides a comprehensive analysis of the global Human Papillomavirus Vaccine landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Human Papillomavirus Vaccine portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Human Papillomavirus Vaccine market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Human Papillomavirus Vaccine and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Human Papillomavirus Vaccine.

This report presents a comprehensive overview, market shares, and growth opportunities of Human Papillomavirus Vaccine market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:

• Bivalent
• Quadrivalent
• Nonavalent

Segmentation by Application:

• Cervical Cancer
• Anal Cancer
• Penile Cancer
• Oropharyngeal Cancer
• Genital Warts
• Others

This report also splits the market by region:

• Americas
• United States
• Canada
• Mexico
• Brazil
• APAC
• China
• Japan
• Korea
• Southeast Asia
• India
• Australia
• Europe
• Germany
• France
• UK
• Italy
• Russia
• Middle East & Africa
• Egypt
• South Africa
• Israel
• Turkey
• GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.

• Merck
• GlaxoSmithKline
• Sanofi
• Johnson & Johnson
• AstraZeneca
• Serum Institute
• Wantai Biological
• KM Biologics
• Bharat Biotech

Key Questions Addressed in this Report

What is the 10-year outlook for the global Human Papillomavirus Vaccine market?
What factors are driving Human Papillomavirus Vaccine market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Human Papillomavirus Vaccine market opportunities vary by end market size?
How does Human Papillomavirus Vaccine break out by Type, by Application?

Contents

1 SCOPE OF THE REPORT

1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

2.1 World Market Overview
  2.1.1 Global Human Papillomavirus Vaccine Annual Sales 2020-2031
  2.1.2 World Current & Future Analysis for Human Papillomavirus Vaccine by Geographic Region, 2020, 2024 & 2031
  2.1.3 World Current & Future Analysis for Human Papillomavirus Vaccine by Country/Region, 2020, 2024 & 2031
2.2 Human Papillomavirus Vaccine Segment by Type
  2.2.1 Bivalent
  2.2.2 Quadrivalent
  2.2.3 Nonavalent
2.3 Human Papillomavirus Vaccine Sales by Type
  2.3.1 Global Human Papillomavirus Vaccine Sales Market Share by Type (2020-2025)
  2.3.2 Global Human Papillomavirus Vaccine Revenue and Market Share by Type (2020-2025)
  2.3.3 Global Human Papillomavirus Vaccine Sale Price by Type (2020-2025)
2.4 Human Papillomavirus Vaccine Segment by Application
  2.4.1 Cervical Cancer
  2.4.2 Anal Cancer
  2.4.3 Penile Cancer
  2.4.4 Oropharyngeal Cancer
  2.4.5 Genital Warts
  2.4.6 Others
2.5 Human Papillomavirus Vaccine Sales by Application
  2.5.1 Global Human Papillomavirus Vaccine Sale Market Share by Application (2020-2025)
  2.5.2 Global Human Papillomavirus Vaccine Revenue and Market Share by Application (2020-2025)
  2.5.3 Global Human Papillomavirus Vaccine Sale Price by Application (2020-2025)

3 GLOBAL BY COMPANY

3.1 Global Human Papillomavirus Vaccine Breakdown Data by Company
  3.1.1 Global Human Papillomavirus Vaccine Annual Sales by Company (2020-2025)
  3.1.2 Global Human Papillomavirus Vaccine Sales Market Share by Company (2020-2025)
3.2 Global Human Papillomavirus Vaccine Annual Revenue by Company (2020-2025)
  3.2.1 Global Human Papillomavirus Vaccine Revenue by Company (2020-2025)
  3.2.2 Global Human Papillomavirus Vaccine Revenue Market Share by Company (2020-2025)
3.3 Global Human Papillomavirus Vaccine Sale Price by Company
3.4 Key Manufacturers Human Papillomavirus Vaccine Producing Area Distribution, Sales Area, Product Type
  3.4.1 Key Manufacturers Human Papillomavirus Vaccine Product Location Distribution
  3.4.2 Players Human Papillomavirus Vaccine Products Offered
3.5 Market Concentration Rate Analysis
  3.5.1 Competition Landscape Analysis
  3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy

4 WORLD HISTORIC REVIEW FOR HUMAN PAPILLOMAVIRUS VACCINE BY GEOGRAPHIC REGION

4.1 World Historic Human Papillomavirus Vaccine Market Size by Geographic Region (2020-2025)
  4.1.1 Global Human Papillomavirus Vaccine Annual Sales by Geographic Region (2020-2025)
  4.1.2 Global Human Papillomavirus Vaccine Annual Revenue by Geographic Region (2020-2025)
4.2 World Historic Human Papillomavirus Vaccine Market Size by Country/Region (2020-2025)
  4.2.1 Global Human Papillomavirus Vaccine Annual Sales by Country/Region (2020-2025)
  4.2.2 Global Human Papillomavirus Vaccine Annual Revenue by Country/Region (2020-2025)
4.3 Americas Human Papillomavirus Vaccine Sales Growth
4.4 APAC Human Papillomavirus Vaccine Sales Growth
4.5 Europe Human Papillomavirus Vaccine Sales Growth
4.6 Middle East & Africa Human Papillomavirus Vaccine Sales Growth

5 AMERICAS

5.1 Americas Human Papillomavirus Vaccine Sales by Country
  5.1.1 Americas Human Papillomavirus Vaccine Sales by Country (2020-2025)
  5.1.2 Americas Human Papillomavirus Vaccine Revenue by Country (2020-2025)
5.2 Americas Human Papillomavirus Vaccine Sales by Type (2020-2025)
5.3 Americas Human Papillomavirus Vaccine Sales by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil

6 APAC

6.1 APAC Human Papillomavirus Vaccine Sales by Region
  6.1.1 APAC Human Papillomavirus Vaccine Sales by Region (2020-2025)
  6.1.2 APAC Human Papillomavirus Vaccine Revenue by Region (2020-2025)
6.2 APAC Human Papillomavirus Vaccine Sales by Type (2020-2025)
6.3 APAC Human Papillomavirus Vaccine Sales by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan

7 EUROPE

7.1 Europe Human Papillomavirus Vaccine by Country
  7.1.1 Europe Human Papillomavirus Vaccine Sales by Country (2020-2025)
  7.1.2 Europe Human Papillomavirus Vaccine Revenue by Country (2020-2025)
7.2 Europe Human Papillomavirus Vaccine Sales by Type (2020-2025)
7.3 Europe Human Papillomavirus Vaccine Sales by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa Human Papillomavirus Vaccine by Country
  8.1.1 Middle East & Africa Human Papillomavirus Vaccine Sales by Country (2020-2025)
  8.1.2 Middle East & Africa Human Papillomavirus Vaccine Revenue by Country (2020-2025)
8.2 Middle East & Africa Human Papillomavirus Vaccine Sales by Type (2020-2025)
8.3 Middle East & Africa Human Papillomavirus Vaccine Sales by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends

10 MANUFACTURING COST STRUCTURE ANALYSIS

10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Human Papillomavirus Vaccine
10.3 Manufacturing Process Analysis of Human Papillomavirus Vaccine
10.4 Industry Chain Structure of Human Papillomavirus Vaccine

11 MARKETING, DISTRIBUTORS AND CUSTOMER

11.1 Sales Channel
  11.1.1 Direct Channels
  11.1.2 Indirect Channels
11.2 Human Papillomavirus Vaccine Distributors
11.3 Human Papillomavirus Vaccine Customer

12 WORLD FORECAST REVIEW FOR HUMAN PAPILLOMAVIRUS VACCINE BY GEOGRAPHIC REGION

12.1 Global Human Papillomavirus Vaccine Market Size Forecast by Region
  12.1.1 Global Human Papillomavirus Vaccine Forecast by Region (2026-2031)
  12.1.2 Global Human Papillomavirus Vaccine Annual Revenue Forecast by Region (2026-2031)
12.2 Americas Forecast by Country (2026-2031)
12.3 APAC Forecast by Region (2026-2031)
12.4 Europe Forecast by Country (2026-2031)
12.5 Middle East & Africa Forecast by Country (2026-2031)
12.6 Global Human Papillomavirus Vaccine Forecast by Type (2026-2031)
12.7 Global Human Papillomavirus Vaccine Forecast by Application (2026-2031)

13 KEY PLAYERS ANALYSIS

13.1 Merck
  13.1.1 Merck Company Information
  13.1.2 Merck Human Papillomavirus Vaccine Product Portfolios and Specifications
  13.1.3 Merck Human Papillomavirus Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
  13.1.4 Merck Main Business Overview
  13.1.5 Merck Latest Developments
13.2 GlaxoSmithKline
  13.2.1 GlaxoSmithKline Company Information
  13.2.2 GlaxoSmithKline Human Papillomavirus Vaccine Product Portfolios and Specifications
  13.2.3 GlaxoSmithKline Human Papillomavirus Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
  13.2.4 GlaxoSmithKline Main Business Overview
  13.2.5 GlaxoSmithKline Latest Developments
13.3 Sanofi
  13.3.1 Sanofi Company Information
  13.3.2 Sanofi Human Papillomavirus Vaccine Product Portfolios and Specifications
  13.3.3 Sanofi Human Papillomavirus Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
  13.3.4 Sanofi Main Business Overview
  13.3.5 Sanofi Latest Developments
13.4 Johnson & Johnson
  13.4.1 Johnson & Johnson Company Information
  13.4.2 Johnson & Johnson Human Papillomavirus Vaccine Product Portfolios and Specifications
  13.4.3 Johnson & Johnson Human Papillomavirus Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
  13.4.4 Johnson & Johnson Main Business Overview
  13.4.5 Johnson & Johnson Latest Developments
13.5 AstraZeneca
  13.5.1 AstraZeneca Company Information
  13.5.2 AstraZeneca Human Papillomavirus Vaccine Product Portfolios and Specifications
  13.5.3 AstraZeneca Human Papillomavirus Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
  13.5.4 AstraZeneca Main Business Overview
  13.5.5 AstraZeneca Latest Developments
13.6 Serum Institute
  13.6.1 Serum Institute Company Information
  13.6.2 Serum Institute Human Papillomavirus Vaccine Product Portfolios and Specifications
  13.6.3 Serum Institute Human Papillomavirus Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
  13.6.4 Serum Institute Main Business Overview
  13.6.5 Serum Institute Latest Developments
13.7 Wantai Biological
  13.7.1 Wantai Biological Company Information
  13.7.2 Wantai Biological Human Papillomavirus Vaccine Product Portfolios and Specifications
  13.7.3 Wantai Biological Human Papillomavirus Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
  13.7.4 Wantai Biological Main Business Overview
  13.7.5 Wantai Biological Latest Developments
13.8 KM Biologics
  13.8.1 KM Biologics Company Information
  13.8.2 KM Biologics Human Papillomavirus Vaccine Product Portfolios and Specifications
  13.8.3 KM Biologics Human Papillomavirus Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
  13.8.4 KM Biologics Main Business Overview
  13.8.5 KM Biologics Latest Developments
13.9 Bharat Biotech
  13.9.1 Bharat Biotech Company Information
  13.9.2 Bharat Biotech Human Papillomavirus Vaccine Product Portfolios and Specifications
  13.9.3 Bharat Biotech Human Papillomavirus Vaccine Sales, Revenue, Price and Gross Margin (2020-2025)
  13.9.4 Bharat Biotech Main Business Overview
  13.9.5 Bharat Biotech Latest Developments

14 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

Table 1. Human Papillomavirus Vaccine Annual Sales CAGR by Geographic Region (2020, 2024 & 2031) & ($ millions)
Table 2. Human Papillomavirus Vaccine Annual Sales CAGR by Country/Region (2020, 2024 & 2031) & ($ millions)
Table 3. Major Players of Bivalent
Table 4. Major Players of Quadrivalent
Table 5. Major Players of Nonavalent
Table 6. Global Human Papillomavirus Vaccine Sales by Type (2020-2025) & (K Doses)
Table 7. Global Human Papillomavirus Vaccine Sales Market Share by Type (2020-2025)
Table 8. Global Human Papillomavirus Vaccine Revenue by Type (2020-2025) & ($ million)
Table 9. Global Human Papillomavirus Vaccine Revenue Market Share by Type (2020-2025)
Table 10. Global Human Papillomavirus Vaccine Sale Price by Type (2020-2025) & (USD/Dose)
Table 11. Global Human Papillomavirus Vaccine Sale by Application (2020-2025) & (K Doses)
Table 12. Global Human Papillomavirus Vaccine Sale Market Share by Application (2020-2025)
Table 13. Global Human Papillomavirus Vaccine Revenue by Application (2020-2025) & ($ million)
Table 14. Global Human Papillomavirus Vaccine Revenue Market Share by Application (2020-2025)
Table 15. Global Human Papillomavirus Vaccine Sale Price by Application (2020-2025) & (USD/Dose)
Table 16. Global Human Papillomavirus Vaccine Sales by Company (2020-2025) & (K Doses)
Table 17. Global Human Papillomavirus Vaccine Sales Market Share by Company (2020-2025)
Table 18. Global Human Papillomavirus Vaccine Revenue by Company (2020-2025) & ($ millions)
Table 19. Global Human Papillomavirus Vaccine Revenue Market Share by Company (2020-2025)
Table 20. Global Human Papillomavirus Vaccine Sale Price by Company (2020-2025) & (USD/Dose)
Table 21. Key Manufacturers Human Papillomavirus Vaccine Producing Area Distribution and Sales Area
Table 22. Players Human Papillomavirus Vaccine Products Offered
Table 23. Human Papillomavirus Vaccine Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
Table 24. New Products and Potential Entrants
Table 25. Market M&A Activity & Strategy
Table 26. Global Human Papillomavirus Vaccine Sales by Geographic Region (2020-2025) & (K Doses)
Table 27. Global Human Papillomavirus Vaccine Sales Market Share Geographic Region (2020-2025)
Table 28. Global Human Papillomavirus Vaccine Revenue by Geographic Region (2020-2025) & ($ millions)
Table 29. Global Human Papillomavirus Vaccine Revenue Market Share by Geographic Region (2020-2025)
Table 30. Global Human Papillomavirus Vaccine Sales by Country/Region (2020-2025) & (K Doses)
Table 31. Global Human Papillomavirus Vaccine Sales Market Share by Country/Region (2020-2025)
Table 32. Global Human Papillomavirus Vaccine Revenue by Country/Region (2020-2025) & ($ millions)
Table 33. Global Human Papillomavirus Vaccine Revenue Market Share by Country/Region (2020-2025)
Table 34. Americas Human Papillomavirus Vaccine Sales by Country (2020-2025) & (K Doses)
Table 35. Americas Human Papillomavirus Vaccine Sales Market Share by Country (2020-2025)
Table 36. Americas Human Papillomavirus Vaccine Revenue by Country (2020-2025) & ($ millions)
Table 37. Americas Human Papillomavirus Vaccine Sales by Type (2020-2025) & (K Doses)
Table 38. Americas Human Papillomavirus Vaccine Sales by Application (2020-2025) & (K Doses)
Table 39. APAC Human Papillomavirus Vaccine Sales by Region (2020-2025) & (K Doses)
Table 40. APAC Human Papillomavirus Vaccine Sales Market Share by Region (2020-2025)
Table 41. APAC Human Papillomavirus Vaccine Revenue by Region (2020-2025) & ($ millions)
Table 42. APAC Human Papillomavirus Vaccine Sales by Type (2020-2025) & (K Doses)
Table 43. APAC Human Papillomavirus Vaccine Sales by Application (2020-2025) & (K Doses)
Table 44. Europe Human Papillomavirus Vaccine Sales by Country (2020-2025) & (K Doses)
Table 45. Europe Human Papillomavirus Vaccine Revenue by Country (2020-2025) & ($ millions)
Table 46. Europe Human Papillomavirus Vaccine Sales by Type (2020-2025) & (K Doses)
Table 47. Europe Human Papillomavirus Vaccine Sales by Application (2020-2025) & (K Doses)
Table 48. Middle East & Africa Human Papillomavirus Vaccine Sales by Country (2020-2025) & (K Doses)
Table 49. Middle East & Africa Human Papillomavirus Vaccine Revenue Market Share by Country (2020-2025)
Table 50. Middle East & Africa Human Papillomavirus Vaccine Sales by Type (2020-2025) & (K Doses)
Table 51. Middle East & Africa Human Papillomavirus Vaccine Sales by Application (2020-2025) & (K Doses)
Table 52. Key Market Drivers & Growth Opportunities of Human Papillomavirus Vaccine
Table 53. Key Market Challenges & Risks of Human Papillomavirus Vaccine
Table 54. Key Industry Trends of Human Papillomavirus Vaccine
Table 55. Human Papillomavirus Vaccine Raw Material
Table 56. Key Suppliers of Raw Materials
Table 57. Human Papillomavirus Vaccine Distributors List
Table 58. Human Papillomavirus Vaccine Customer List
Table 59. Global Human Papillomavirus Vaccine Sales Forecast by Region (2026-2031) & (K Doses)
Table 60. Global Human Papillomavirus Vaccine Revenue Forecast by Region (2026-2031) & ($ millions)
Table 61. Americas Human Papillomavirus Vaccine Sales Forecast by Country (2026-2031) & (K Doses)
Table 62. Americas Human Papillomavirus Vaccine Annual Revenue Forecast by Country (2026-2031) & ($ millions)
Table 63. APAC Human Papillomavirus Vaccine Sales Forecast by Region (2026-2031) & (K Doses)
Table 64. APAC Human Papillomavirus Vaccine Annual Revenue Forecast by Region (2026-2031) & ($ millions)
Table 65. Europe Human Papillomavirus Vaccine Sales Forecast by Country (2026-2031) & (K Doses)
Table 66. Europe Human Papillomavirus Vaccine Revenue Forecast by Country (2026-2031) & ($ millions)
Table 67. Middle East & Africa Human Papillomavirus Vaccine Sales Forecast by Country (2026-2031) & (K Doses)
Table 68. Middle East & Africa Human Papillomavirus Vaccine Revenue Forecast by Country (2026-2031) & ($ millions)
Table 69. Global Human Papillomavirus Vaccine Sales Forecast by Type (2026-2031) & (K Doses)
Table 70. Global Human Papillomavirus Vaccine Revenue Forecast by Type (2026-2031) & ($ millions)
Table 71. Global Human Papillomavirus Vaccine Sales Forecast by Application (2026-2031) & (K Doses)
Table 72. Global Human Papillomavirus Vaccine Revenue Forecast by Application (2026-2031) & ($ millions)
Table 73. Merck Basic Information, Human Papillomavirus Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 74. Merck Human Papillomavirus Vaccine Product Portfolios and Specifications
Table 75. Merck Human Papillomavirus Vaccine Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 76. Merck Main Business
Table 77. Merck Latest Developments
Table 78. GlaxoSmithKline Basic Information, Human Papillomavirus Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 79. GlaxoSmithKline Human Papillomavirus Vaccine Product Portfolios and Specifications
Table 80. GlaxoSmithKline Human Papillomavirus Vaccine Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 81. GlaxoSmithKline Main Business
Table 82. GlaxoSmithKline Latest Developments
Table 83. Sanofi Basic Information, Human Papillomavirus Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 84. Sanofi Human Papillomavirus Vaccine Product Portfolios and Specifications
Table 85. Sanofi Human Papillomavirus Vaccine Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 86. Sanofi Main Business
Table 87. Sanofi Latest Developments
Table 88. Johnson & Johnson Basic Information, Human Papillomavirus Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 89. Johnson & Johnson Human Papillomavirus Vaccine Product Portfolios and Specifications
Table 90. Johnson & Johnson Human Papillomavirus Vaccine Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 91. Johnson & Johnson Main Business
Table 92. Johnson & Johnson Latest Developments
Table 93. AstraZeneca Basic Information, Human Papillomavirus Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 94. AstraZeneca Human Papillomavirus Vaccine Product Portfolios and Specifications
Table 95. AstraZeneca Human Papillomavirus Vaccine Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 96. AstraZeneca Main Business
Table 97. AstraZeneca Latest Developments
Table 98. Serum Institute Basic Information, Human Papillomavirus Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 99. Serum Institute Human Papillomavirus Vaccine Product Portfolios and Specifications
Table 100. Serum Institute Human Papillomavirus Vaccine Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 101. Serum Institute Main Business
Table 102. Serum Institute Latest Developments
Table 103. Wantai Biological Basic Information, Human Papillomavirus Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 104. Wantai Biological Human Papillomavirus Vaccine Product Portfolios and Specifications
Table 105. Wantai Biological Human Papillomavirus Vaccine Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 106. Wantai Biological Main Business
Table 107. Wantai Biological Latest Developments
Table 108. KM Biologics Basic Information, Human Papillomavirus Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 109. KM Biologics Human Papillomavirus Vaccine Product Portfolios and Specifications
Table 110. KM Biologics Human Papillomavirus Vaccine Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 111. KM Biologics Main Business
Table 112. KM Biologics Latest Developments
Table 113. Bharat Biotech Basic Information, Human Papillomavirus Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 114. Bharat Biotech Human Papillomavirus Vaccine Product Portfolios and Specifications
Table 115. Bharat Biotech Human Papillomavirus Vaccine Sales (K Doses), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2020-2025)
Table 116. Bharat Biotech Main Business
Table 117. Bharat Biotech Latest Developments

List Of Figures

LIST OF FIGURES

Figure 1. Picture of Human Papillomavirus Vaccine
Figure 2. Human Papillomavirus Vaccine Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Human Papillomavirus Vaccine Sales Growth Rate 2020-2031 (K Doses)
Figure 7. Global Human Papillomavirus Vaccine Revenue Growth Rate 2020-2031 ($ millions)
Figure 8. Human Papillomavirus Vaccine Sales by Geographic Region (2020, 2024 & 2031) & ($ millions)
Figure 9. Human Papillomavirus Vaccine Sales Market Share by Country/Region (2024)
Figure 10. Human Papillomavirus Vaccine Sales Market Share by Country/Region (2020, 2024 & 2031)
Figure 11. Product Picture of Bivalent
Figure 12. Product Picture of Quadrivalent
Figure 13. Product Picture of Nonavalent
Figure 14. Global Human Papillomavirus Vaccine Sales Market Share by Type in 2025
Figure 15. Global Human Papillomavirus Vaccine Revenue Market Share by Type (2020-2025)
Figure 16. Human Papillomavirus Vaccine Consumed in Cervical Cancer
Figure 17. Global Human Papillomavirus Vaccine Market: Cervical Cancer (2020-2025) & (K Doses)
Figure 18. Human Papillomavirus Vaccine Consumed in Anal Cancer
Figure 19. Global Human Papillomavirus Vaccine Market: Anal Cancer (2020-2025) & (K Doses)
Figure 20. Human Papillomavirus Vaccine Consumed in Penile Cancer
Figure 21. Global Human Papillomavirus Vaccine Market: Penile Cancer (2020-2025) & (K Doses)
Figure 22. Human Papillomavirus Vaccine Consumed in Oropharyngeal Cancer
Figure 23. Global Human Papillomavirus Vaccine Market: Oropharyngeal Cancer (2020-2025) & (K Doses)
Figure 24. Human Papillomavirus Vaccine Consumed in Genital Warts
Figure 25. Global Human Papillomavirus Vaccine Market: Genital Warts (2020-2025) & (K Doses)
Figure 26. Human Papillomavirus Vaccine Consumed in Others
Figure 27. Global Human Papillomavirus Vaccine Market: Others (2020-2025) & (K Doses)
Figure 28. Global Human Papillomavirus Vaccine Sale Market Share by Application (2024)
Figure 29. Global Human Papillomavirus Vaccine Revenue Market Share by Application in 2025
Figure 30. Human Papillomavirus Vaccine Sales by Company in 2025 (K Doses)
Figure 31. Global Human Papillomavirus Vaccine Sales Market Share by Company in 2025
Figure 32. Human Papillomavirus Vaccine Revenue by Company in 2025 ($ millions)
Figure 33. Global Human Papillomavirus Vaccine Revenue Market Share by Company in 2025
Figure 34. Global Human Papillomavirus Vaccine Sales Market Share by Geographic Region (2020-2025)
Figure 35. Global Human Papillomavirus Vaccine Revenue Market Share by Geographic Region in 2025
Figure 36. Americas Human Papillomavirus Vaccine Sales 2020-2025 (K Doses)
Figure 37. Americas Human Papillomavirus Vaccine Revenue 2020-2025 ($ millions)
Figure 38. APAC Human Papillomavirus Vaccine Sales 2020-2025 (K Doses)
Figure 39. APAC Human Papillomavirus Vaccine Revenue 2020-2025 ($ millions)
Figure 40. Europe Human Papillomavirus Vaccine Sales 2020-2025 (K Doses)
Figure 41. Europe Human Papillomavirus Vaccine Revenue 2020-2025 ($ millions)
Figure 42. Middle East & Africa Human Papillomavirus Vaccine Sales 2020-2025 (K Doses)
Figure 43. Middle East & Africa Human Papillomavirus Vaccine Revenue 2020-2025 ($ millions)
Figure 44. Americas Human Papillomavirus Vaccine Sales Market Share by Country in 2025
Figure 45. Americas Human Papillomavirus Vaccine Revenue Market Share by Country (2020-2025)
Figure 46. Americas Human Papillomavirus Vaccine Sales Market Share by Type (2020-2025)
Figure 47. Americas Human Papillomavirus Vaccine Sales Market Share by Application (2020-2025)
Figure 48. United States Human Papillomavirus Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 49. Canada Human Papillomavirus Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 50. Mexico Human Papillomavirus Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 51. Brazil Human Papillomavirus Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 52. APAC Human Papillomavirus Vaccine Sales Market Share by Region in 2025
Figure 53. APAC Human Papillomavirus Vaccine Revenue Market Share by Region (2020-2025)
Figure 54. APAC Human Papillomavirus Vaccine Sales Market Share by Type (2020-2025)
Figure 55. APAC Human Papillomavirus Vaccine Sales Market Share by Application (2020-2025)
Figure 56. China Human Papillomavirus Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 57. Japan Human Papillomavirus Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 58. South Korea Human Papillomavirus Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 59. Southeast Asia Human Papillomavirus Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 60. India Human Papillomavirus Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 61. Australia Human Papillomavirus Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 62. China Taiwan Human Papillomavirus Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 63. Europe Human Papillomavirus Vaccine Sales Market Share by Country in 2025
Figure 64. Europe Human Papillomavirus Vaccine Revenue Market Share by Country (2020-2025)
Figure 65. Europe Human Papillomavirus Vaccine Sales Market Share by Type (2020-2025)
Figure 66. Europe Human Papillomavirus Vaccine Sales Market Share by Application (2020-2025)
Figure 67. Germany Human Papillomavirus Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 68. France Human Papillomavirus Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 69. UK Human Papillomavirus Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 70. Italy Human Papillomavirus Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 71. Russia Human Papillomavirus Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 72. Middle East & Africa Human Papillomavirus Vaccine Sales Market Share by Country (2020-2025)
Figure 73. Middle East & Africa Human Papillomavirus Vaccine Sales Market Share by Type (2020-2025)
Figure 74. Middle East & Africa Human Papillomavirus Vaccine Sales Market Share by Application (2020-2025)
Figure 75. Egypt Human Papillomavirus Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 76. South Africa Human Papillomavirus Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 77. Israel Human Papillomavirus Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 78. Turkey Human Papillomavirus Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 79. GCC Countries Human Papillomavirus Vaccine Revenue Growth 2020-2025 ($ millions)
Figure 80. Manufacturing Cost Structure Analysis of Human Papillomavirus Vaccine in 2025
Figure 81. Manufacturing Process Analysis of Human Papillomavirus Vaccine
Figure 82. Industry Chain Structure of Human Papillomavirus Vaccine
Figure 83. Channels of Distribution
Figure 84. Global Human Papillomavirus Vaccine Sales Market Forecast by Region (2026-2031)
Figure 85. Global Human Papillomavirus Vaccine Revenue Market Share Forecast by Region (2026-2031)
Figure 86. Global Human Papillomavirus Vaccine Sales Market Share Forecast by Type (2026-2031)
Figure 87. Global Human Papillomavirus Vaccine Revenue Market Share Forecast by Type (2026-2031)
Figure 88. Global Human Papillomavirus Vaccine Sales Market Share Forecast by Application (2026-2031)
Figure 89. Global Human Papillomavirus Vaccine Revenue Market Share Forecast by Application (2026-2031)